Overview

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Lenograstim
Paclitaxel